Self-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency

Rotigotine (RTG) is a non-ergoline dopamine agonist and an approved drug for treating Parkinson’s disease. However, its clinical use is limited due to various problems, viz. poor oral bioavailability (<1%), low aqueous solubility, and extensive first-pass metabolism. In this study, rotigotine-loa...

Descripción completa

Detalles Bibliográficos
Autores principales: Saha, Paramita, Singh, Prabhjeet, Kathuria, Himanshu, Chitkara, Deepak, Pandey, Murali Monohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052746/
https://www.ncbi.nlm.nih.gov/pubmed/36986712
http://dx.doi.org/10.3390/pharmaceutics15030851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052746/
https://www.ncbi.nlm.nih.gov/pubmed/36986712
http://dx.doi.org/10.3390/pharmaceutics15030851

Ejemplares similares